Louvain-la-Neuve, Belgium, April 7th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing ...

Kepler Capital analyst Matthias Maenhaut maintained a Hold rating on Ion Beam Applications SA IBA (0GZK – Research Report) on April 2 and set ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Finally, the team continues to explore other applications for the HODOTRAN ... in advanced semiconductor processing using an ion beam technology. IBA will support mi2 in advancing towards an ...

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates ...

Louvain-la-Neuve, Belgium, 07 April, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, hosted its Capital Markets Day (CMD) today at its ...

Tri-Service General Hospital in Taiwan has entered a contract with Ion Beam Applications (IBA) for a ProteusONE compact ...

The ion beam provides control over attributes such as coercivity and anisotropy, which are important for high-density data storage and sensor applications. This capability contributes to the ...

Ion Beam Applications SA (IBAB), a leader in proton therapy systems with a market capitalization of €382.41 million, reported record revenue for the first quarter of 2025, marking a 7% increase ...

In a report released on March 24, Matthias Maenhaut from Kepler Capital maintained a Hold rating on Ion Beam Applications SA IBA (0GZK – ...

1 Day IOBCF -12.29% DJIA -2.99% Russell 2K -6.04% Health Care/Life Sciences 0.87% ...